<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282215</url>
  </required_header>
  <id_info>
    <org_study_id>CLT008-03</org_study_id>
    <nct_id>NCT02282215</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia</brief_title>
  <official_title>An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellerant Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellerant Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the safety and efficacy of CLT-008 as an extra&#xD;
      supportive care measure after induction chemotherapy for patients with acute myeloid leukemia&#xD;
      (AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prolonged period of severe neutropenia caused by induction chemotherapy for the treatment&#xD;
      of AML is associated with a nearly universal risk of febrile neutropenia. Standard supportive&#xD;
      care strategies include administration of prophylactic anti-bacterial and anti-fungal agents,&#xD;
      but serious breakthrough bacterial and fungal infections still occur. Granulocyte&#xD;
      colony-stimulating factor (G-CSF; filgrastim, Neupogen®) has been shown to shorten the&#xD;
      duration of severe neutropenia, fever, antibiotic use and hospitalization following induction&#xD;
      chemotherapy for AML. CLT-008, a human allogeneic myeloid progenitor cell product, is&#xD;
      intended to provide the cellular target for G-CSF to produce neutrophils during the period of&#xD;
      chemotherapy-induced bone marrow suppression when the patient's own progenitor cells may be&#xD;
      limited in responding to G-CSF. It is hypothesized that the production of allogeneic&#xD;
      neutrophils from CLT-008 will be sufficient to mitigate the infection-related consequences of&#xD;
      induction chemotherapy for AML.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">September 22, 2017</completion_date>
  <primary_completion_date type="Actual">September 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of febrile episodes (fever)</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to absolute neutrophil count (ANC) recovery</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of febrile neutropenia</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of infection</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of mucositis</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infusion reactions</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Graft-versus-Host Disease (GVHD)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AE)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAE)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Neutropenia</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>CLT-008 low dose with G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLT-008 high dose with G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLT-008 with G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CLT-008</intervention_name>
    <description>Single intravenous infusion</description>
    <arm_group_label>CLT-008 high dose with G-CSF</arm_group_label>
    <arm_group_label>CLT-008 low dose with G-CSF</arm_group_label>
    <arm_group_label>CLT-008 with G-CSF</arm_group_label>
    <other_name>human allogeneic myeloid progenitor cells (hMPC)</other_name>
    <other_name>romyelocel-L</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Daily subcutaneous injections</description>
    <arm_group_label>CLT-008 high dose with G-CSF</arm_group_label>
    <arm_group_label>CLT-008 low dose with G-CSF</arm_group_label>
    <arm_group_label>CLT-008 with G-CSF</arm_group_label>
    <arm_group_label>G-CSF</arm_group_label>
    <other_name>Neupogen (filgrastim)</other_name>
    <other_name>granulocyte colony-stimulating factor</other_name>
    <other_name>Zarxio</other_name>
    <other_name>Granix (tbo-filgrastim)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute myeloid leukemia arising de novo (per European LeukemiaNet)&#xD;
&#xD;
          2. Treated with any established chemotherapy regimen based on either:&#xD;
&#xD;
               1. 7+3: Standard-dose cytarabine 100-200 mg per meter squared continuous infusion&#xD;
                  for 7 days with idarubicin 12 mg per meter squared or daunorubicin 45-90 mg per&#xD;
                  meter squared for 3 days&#xD;
&#xD;
               2. High-dose cytarabine-based (HIDAC) chemotherapy administering a total cytarabine&#xD;
                  dose of ≥ 4 g per meter squared alone or in combination with other anti-leukemic&#xD;
                  agents (for example, anthracyclines, purine nucleoside inhibitors, etoposide,&#xD;
                  etc.)&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening or by&#xD;
             the day chemotherapy is initiated&#xD;
&#xD;
          4. Adequate respiratory function with a room air oxygen saturation of at least 92%&#xD;
&#xD;
          5. Adequate cardiac function defined as an ejection fraction of at least 45%&#xD;
&#xD;
          6. Serum bilirubin ≤ 1.5 times the upper limits of normal. Subjects with a history of&#xD;
             Gilbert's syndrome may be enrolled if the total bilirubin is &lt; 3 mg/dL with an&#xD;
             indirect bilirubin of &gt; 1.5 mg/dL&#xD;
&#xD;
          7. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times&#xD;
             upper limits of normal prior to chemotherapy&#xD;
&#xD;
          8. Serum creatinine ≤ 2 times upper limits of normal or estimated glomerular filtration&#xD;
             rate ≥ 60 mL/min/1.73 meter squared per Modification of Diet in Renal Disease equation&#xD;
             (MDRD)&#xD;
&#xD;
          9. All subjects, except post-menopausal women, must be willing to utilize a highly&#xD;
             effective method of contraception throughout the study&#xD;
&#xD;
         10. Adequately informed of the nature and risks of the study with written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast feeding&#xD;
&#xD;
          2. Overt central nervous system manifestations of leukemia at diagnosis&#xD;
&#xD;
          3. Specifically diagnosed and uncontrolled fungal, bacterial, viral, or other infection&#xD;
             (e.g. confirmed sepsis, pneumonia, abscess, cellulitis, etc.) at the day chemotherapy&#xD;
             is initiated. &quot;Uncontrolled&quot; is defined as exhibiting ongoing signs and symptoms of&#xD;
             infection without improvement despite antimicrobial or other treatment.&#xD;
&#xD;
          4. AML subtype M3 (promyelocytic leukemia)&#xD;
&#xD;
          5. Previous chemotherapy for AML&#xD;
&#xD;
          6. History of or current human immunodeficiency virus (HIV) or hepatitis C virus&#xD;
             infection&#xD;
&#xD;
          7. History of or current clinically significant immunodeficiency&#xD;
&#xD;
          8. Known contraindication to receiving G-CSF&#xD;
&#xD;
          9. History of or current clinically significant alloimmunization to leukocyte antigens&#xD;
&#xD;
         10. Participation in another clinical study within 28 days of the day chemotherapy is&#xD;
             initiated, in which the study drug or device may influence hematopoiesis.&#xD;
             Co-enrollment in another study is allowed in cases where the investigational therapy&#xD;
             under study is a version of an acceptable chemotherapy regimen for this study per the&#xD;
             inclusion criteria.&#xD;
&#xD;
         11. Receiving any agent concurrently with CLT-008 infusion which inhibits cell division&#xD;
             (e.g., methotrexate or hydroxyurea)&#xD;
&#xD;
         12. Acute or chronic medical disorder that, in the opinion of the investigator or medical&#xD;
             monitor, may prevent the subject from completing participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Reed, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cellerant Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Shands Cancer Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Medical Faculty Foundation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Worcester</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Physicians BMT Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Veterans Affairs Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College - New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>October 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <disposition_first_submitted>September 21, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>September 25, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 27, 2018</disposition_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fever</keyword>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Infection</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Myeloid progenitor cells</keyword>
  <keyword>Neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

